Assays - Pantoprazole

Bioavailability of a crushed Pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated Pantoprazole tablet

Author: L.M. Ley, B. Stahlheber-Dilg, P. Sander, R. Huber, H.J. Mascher, P.W. Lücker
Publisher: Methods Find Exp Clin Pharmacol. 2001, 23, 41-45

Intra-esophageal pH profiles and pharmacokinetics of Pantoprazole and Esomeprazole: a crossover study in patients with GERD

B. Simon, P. Müller, O. Pascu, G. Gatz, P. Sander, R. Huber, H. Mascher
Eur J Gastroenterol Hepatol. 2003, 15, 791-799

Bioavailability of a crushed Pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated antoprazole tablet

L.M. Ley, B. Stahlheber-Dilg, P. Sander, R. Huber, H. Mascher and P.W. Lücker
Methods Find Exp Clin Pharmacol. 2001, 23, 41-45

Bioavailability of a crushed Pantoprazole tablet after buffering with sodium hydrogen-carbonate or magaldrate relative to the intact enteric coated antoprazole tablet

L.M. Ley, B. Stahlheber-Dilg, P. Sander, R. Huber, H. Mascher and P.W. Lücker
Methods Find Exp. Clin. Pharmacol. 2001, 23, 41 - 45

Lack-of-Interaction between Pantoprazole and Piroxicam in man

H. Bliesath, M. Hartmann, J. Maier, R. Huber, R. Lühmann, Th. Bethke, W. Wurst, H. Mascher
UEGW 11/2000 Brussels

Pantoprazole lacks induction of CYP1A2 activity in man

M. Hartmann, K. Zech, H. Bliesath, V. W. Steinijans, H. Koch, W. Wurst and H. Mascher
Int. J. Clin. Pharmacol. Ther. , Vol. 37 (4) 1999, 159-164

Comparison of the Pharmacodynamics and Pharmacokinetics of Pantoprazole (40 mg) as Compared to Omeprazole MUPS (20mg) after Repeated Oral Dose Administration

A. Ehrlich, P.W. Lücker, A. Wiedemann, P. Sander, R. Huber and H. Mascher
Methods Find Exp Clin Pharmacol 1999, 21 (1), 47-51

Pantoprazole does not interact with the pharmacokinetics of carbamazepine

R. Huber, H. Bliesath, M. Hartmann, V. W. Steinijans, H. Koch, H. Mascher and W. Wurst
Int. J. Clin. Pharmacol. Ther. 36 (1998), 521-524

Lack of pharmacokinetic and pharmacodynamic interaction between Pantoprazol and Glibenclamid in humans

I.E. Walter-Sack, H. Bliesath, F. Stötzer, R. Huber, V. W. Steinijans, R. Ding, H. Mascher and W. Wurst
Clin. Drug Invest. 15 (1998), 253-260

Pantoprazole does not influence Metoprolol Pharmacokinetics and Pharmacodynamics in man

H. J. Koch, M. Hartmann, H. Bliesath, R. Huber, V. W. Steinijans, H. Mascher, W. Wurst
Gastroenterology, 110 (Suppl.) (1996), A 158

Pantoprazole does not Interact with the Pharmacokinetics of Carbamazepine

R. Huber, H. Bliesath, M. Hartmann, H. Koch, V. W. Steinijans, H. Mascher, W. Wurst
Gastroenterology, 110 (Suppl.) (1996), A 137

Pantoprazole has no Influence on Steady State Pharmacokinetics and Pharmacodynamics of Metoprolol in Healthy Volunteers

H.J. Koch, M. Hartmann, H. Bliesath, R. Huber, V. W. Steinijans, H. Mascher, W. Wurst
Int. J. Clin. Pharmacol. Ther. 34 (1996), 420-423

Lack of Pharmacokinetic Interaction between Pantoprazole and Diclofenac

H. Bliesath, R. Huber, V. W. Stenijans, H. J. Koch, W. Wurst and H. Mascher
Int. J. Clin. Pharmacol. Ther. 34 (1996), 152-156

Pantoprazole does not influence CYPIA2 activity in man

M. Hartmann, H. Bliesath, K. Zech, H. Koch, V. W. Steinijans, W. Wurst, H. Mascher
Gastroenterology, 108 (Suppl.) (1995), A 109